-
-
[1]Lavanchy D.Hepatitis B virus epidemiology, disease burden, treat-ment, and current and emerging prevention and controlmeasures[J].J Viral Hepat, 2004, 11∶97-107. [2]Miyakawa Y, Mizokami M.Classifying hepatitis B virusgenotypes[J].Intervirology, 2003, 46∶329-338. [3]Hannoun C, Krogsgaard K, Horal P, et al.Genotype Mixtures ofHepatitis B Virus in Patients Treated with Interferon[J].J InfectDis, 2002, 186∶752-759. [4]Toan NL, Song LH, Kremsner PG, et al.Impact of the hepatitis Bvirus genotype and genotype mixtures on the course of liver disease inVietnam[J].Hepatology, 2006, 43∶1375-1384. [5]Liu CJ, Chen BF, Chen PJ, et al.Role of Hepatitis B Virus Pre-core/Core Promoter Mutations and Serum Viral Load on NoncirrhoticHepatocellular Carcinoma:A Case-Control Study[J].The J InfectDis, 2006, 194∶594-599. [6]Kao JH, Chen PJ, Lai MY, et al.Hepatitis B genotypes correlatewith clinical outcomes in patients with chronic hepatitis B[J].Gas-troenterology, 2000, 118∶554-559. [7]Molin GD, Poli A, Croce LS, et al.Hepatitis B Virus Genotypes, Core Promoter Variants, and Precore Stop Codon Variants in PatientsInfected Chronically in North-Eastern Italy[J].J Med Virol, 2006, 78∶734-740. [8]Kumar A, Kumar SI, Pandey R, et al.Hepatitis B virus genotype Ais more often associated with severe liver disease in northern Indiathan is genotype D[J].Indian J Gastroenterol, 2005, 24∶19-22. [9]Chu CJ, Hussain M, Lok AS.Hepatitis B virus genotype B is associ-ated with earlier HBeAg seroconversion compared with hepatitis B vi-rus genotype C[J].Gastroenterology, 2002, 122∶1756-1762. [10]Wai CT, Chu CJ, Hussain M, et al.HBVgenotype B is associatedwith better response to interferon therapy in HBeAg (+) chronichepatitis than genotype C[J].Hepatology, 2002, 32∶1425-1430. [11]肖扬, 胡操寒, 周岳进, 等.乙型肝炎病毒基因型对干扰素α-2b应答的影响[J].临床肝胆病杂志, 2006, 22∶105-106. [12]Erhardt A, Blondin D, Hauck K, et al.Response to interferon alfais hepatitis B virus genotype dependent:genotype Ais more sensitiveto interferon than genotype D[J].Gut, 2005, 54∶1009-1013. [13]Hou J, Schilling R, Janssen HL, et al.Molecular characteristics ofhepatitis B virus genotype A confer a higher response to interferontreatment[J].J Hepatol, 2001, 34 (Suppl 1) ∶15. [14]Flink HJ, Zonneveld MV, Hansen BE, et al.Treatment with Peg-Interferonα-2b for HBeAg-Positive Chronic Hepatitis B:HBsAgLoss Is Associated with HBV Genotype[J].Am J Gastroenterol, 2006, 101∶297-303. [15]Janssen HL, van Zonneveld M, Senturk H, et al.Pegylated inter-feron alfa-2b alone or in combination with lamiudine for HBeAg-positive chronic hepatitis B:a randomised trial[J].Lancet, 2005, 365∶123-129. [16]Chan HL, Wong ML, Hui AY, et al.Hepatitis B virus genotypehas no impact on hepatitis B e antigen seroconversion after lamivudinetreatment[J].World J Gastroenterol, 2003, 9∶2695-2697. [17]Orito E, Fujiwara K, Tanaka Y, et al.Acase-control study of re-sponse to lamivudine therapy for2 years in Japanese and Chinese pa-tients chronically infected with hepatitis B virus of genotypes Bj, Baand C[J].Hepatol Res, 2006, 35∶127-134. [18]Chien RN, Yeh CT, Tsai SL, et al.Determinants for sustainedHBeAg response to lamivudine therapy[J].Hepatology, 2003, 38∶1267-1273. [19]Thakur V, Sarin SK, Rehman S, et al.Role of HBV genotype inpredicting response to lamivudine therapy in patients with chronichepatitis B[J].Indian J Gastroenterol, 2005, 24∶12-15. [20]Akuta N, Suzuki F, Kobayashi M, et al.The influence of hepatitisB virus genotype on the development of lamivudine resistance duringlong-term treatment[J].J Hepatol, 2003, 38∶315-321. [21]Buti M, Cotrina M, Valdes A, et al.Is hepatitis B virus subtypetesting useful in predicting virological response and resistance to lami-vudine?[J].J Hepatol, 2002, 36∶445-446. [22]Kobayashi M, Suzuki F, Akuta N, et al.Response to Long-TermLamivudine Treatment in Patients Infected With Hepatitis B VirusGenotypes A, B, and C[J].J Med Virol, 2006, 78∶1276-1283. [23]Westland C, Delaney W, Yang H, et al.Hepatitis B virus geno-types and virologic response in 694 patients in phaseⅢstudies ofadefovir dipivoxil[J].Gastroenterology, 2003, 125∶107-16. [24]Lurie Y, Manns MP, Gish RG, et al.The efficacy of entecavir issimilar regardless of disease-related baseline subgroups in treatmentof nucleoside-naive, HBeAg (+) and HBeAg (-) patients withchronic hepatitis B[J].J Hepatol, 2005, 42 (suppl 2) ∶184.
本文二维码
计量
- 文章访问数: 2054
- HTML全文浏览量: 4
- PDF下载量: 1011
- 被引次数: 0